Investigational drug · Phase 2
PM54
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Advanced Solid Tumor, Advanced Malignancies.
Phase 2Last checked: Nov 19, 2026Latest source record: Oct 13, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
5
Any phase or sponsor naming "PM54"
First trial start
2026
May 21, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "PM54", any sponsor or status.
Conditions studied
As listed on its trial records.
- Advanced Solid Tumor
- Advanced Malignancies
Approved drugs for the same conditions: Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "PM54" as an intervention, largest first.
- Study of PM54 in Combination With Cytotoxic and Targeted Agents in Adult Participants With Advanced MalignanciesNot yet recruiting
PharmaMarIndustry
NCT07839819 · 231 participants (planned) · Start Nov 12, 2026 · Primary completion Sep 27, 2029
Drug: PM54; Irinotecan and 1 more · For: Advanced Solid Tumor
Sites: Omaha, Nebraska; Houston, Texas; Bordeaux, France · 9 sites in all
PharmaMarIndustry
NCT05841563 · 125 participants (planned) · Start Apr 28, 2023 · Primary completion Dec 30, 2026
Drug: PM54 · For: Advanced Solid Tumor
Sites: San Antonio, Texas; Anderlecht, Belgium; Madrid, Spain
- Study of PM54 in Combination With Immunotherapy in Adult Participants With Advanced MalignanciesRecruiting
PharmaMarIndustry
NCT07644039 · 119 participants (planned) · Start May 21, 2026 · Primary completion Apr 2, 2029
Drug: Pembrolizumab; PM54 · For: Advanced Malignancies
Sites: New York, New York; Fort Worth, Texas; Houston, Texas · 11 sites in all
- Assessing the Safety/Efficacy of Asacol® Given Every 12 Hours to Children and Adolescents With Active Ulcerative ColitisPivotal-lookingCompleted
Warner ChilcottIndustry
NCT00713310 · 83 participants · Start Dec 2008 · Primary completion Mar 2011
Drug: Asacol 400 mg; Asacol 400 mg · For: Ulcerative Colitis
Sites: Birmingham, Alabama; Phoenix, Arizona; Loma Linda, California · 42 sites in all
- Assessing the Safety/Efficacy of Asacol® Given Every 12 Hours to Children and Adolescents for the Maintenance of Remission of Ulcerative ColitisPivotal-lookingTerminated
Warner ChilcottIndustry
NCT01004185 · 39 participants · Start Oct 2009 · Primary completion Mar 2011
Drug: Asacol 400 mg; Asacol 400 mg · For: Ulcerative Colitis
Sites: Birmingham, Alabama; Phoenix, Arizona; Loma Linda, California · 51 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Antitumor Activity of Novel Transcriptional Inhibitors Ecubectedin and PM54 in Soft Tissue Sarcoma Patient-Derived Xenografts.
Gorgels D, Wang CC, De Cock L, et al. · Cancer Res Commun 2026
- The structures of ecteinascidin anticancer agents bound to DNA shed light on their mechanism of action.
Darrière T, Ruiz FM, Martínez-Díez M, et al. · Nucleic Acids Res 2026
- Ecteinascidin synthetic analogues: a new class of selective inhibitors of transcription, exerting immunogenic cell death in refractory malignant pleural mesothelioma.
Salaroglio IC, Aviles P, Kopecka J, et al. · J Exp Clin Cancer Res 2024
- Molecular characterization of a new powdery mildew resistance gene Pm54 in soft red winter wheat.
Hao Y, Parks R, Cowger C, et al. · Theor Appl Genet 2015
Also in development for Advanced Solid Tumor
- I-DXdDS-7300a, MK-2400Phase 317 trials
Merck & Co. · Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, Esophageal Squamous Cell Carcinoma
- HS-20093Ris-Rez, Risvutatug rezetecanPhase 316 trials
Hansoh BioMedical R&D Company · Neoplasms, Lung, Sarcoma, Osteosarcoma
- LBL-024Phase 311 trials
Nanjing Leads Biolabs Co.,Ltd · Advanced Solid Tumour, Advanced Extrapulmonary Neuroendocrine Carcinoma, Metastatic Colorectal Carcinoma
- TQB2102Phase 311 trials
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. · Breast Cancer, HER2-positive Breast Cancer, Gynecological Tumors
- YL201Tambotatug Pelitecan, Tam-PeliPhase 311 trials
MediLink Therapeutics (Suzhou) Co., Ltd. · Advanced Solid Tumor, Small Cell Lung Cancer, Metastatic Pancreatic Cancer
- ZG005Phase 311 trials
Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Advanced Solid Tumor, Lymphoma, Non-small Cell Lung Cancer
- R-DXdDS 6000a, MK-5909Phase 310 trials
Merck & Co. · Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cancer
- QLC5508MHB088CPhase 39 trials
Qilu Pharmaceutical Co., Ltd. · Advanced/Metastatic Solid Tumors, Advanced Malignant Solid Tumor, Extrapulmonary Neuroendocrine Carcinoma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.